Abstract
In The Lancet, Richard Gray and the UK PD MED Collaborative Group1 report the highly anticipated results of a very large, pragmatic trial assessing outcomes during a median follow-up of 3 years and maximum 7 years in patients with early Parkinson's disease. A total of 1620 patients were managed with three different initial treatment regimens: levodopa (528 patients) or two levodopa-sparing approaches, either a dopamine agonist (632 patients) or a monoamine oxidase type B inhibitor (MAOBI; 460 patients).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
